微调五号方或联合生物反应调节剂对Ⅲ、Ⅳ期肾癌患者生存质量影响的临床研究  

The Clinical Research of WD-5 with Biological Response Modifiers with IFN-α2b& IL-2 in the Quality of Life of Renal Cell Carcinoma Patients of Stage Ⅲ、Ⅳ

作　　者：张辰岑[1] 尤建良[1] 

机构地区：[1]无锡市中医医院肿瘤科,江苏无锡214000

出　　处：《中华中医药学刊》2016年第2期447-450,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：无锡市卫生局卫生科技项目(201206)

摘　　要：目的:观察微调五号方(WD-5)或WD-5联合生物反应调节剂(IL-2和IFN-α2b)对Ⅲ、Ⅳ期肾癌患者生存质量的影响。方法:Ⅲ、Ⅳ期肾癌患者共40例,按随机数字表法分为治疗组(WD-5+生物反应调节剂)及对照组(单纯生物反应调节剂),治疗2个疗程后观察两组患者治疗前后实体瘤大小、临床常见症状改善情况、Karnofsky体力状况评分、细胞免疫功能水平、肿瘤标志物水平、生命质量评分,以及治疗毒副反应。结果:WD-5+生物反应调节剂在缓解临床症状、提高卡氏评分、提高细胞免疫功能、降低肿瘤标志物水平、提高患者生命质量、减轻生物反应调节剂治疗的毒副反应方面优于单纯使用生物反应调节剂。结论:WD-5联合IL-2和IFN-α2b治疗Ⅲ、Ⅳ期肾细胞癌,能够缓解患者临床症状和体征,提高患者细胞免疫功能,改善体力状况,提高生命质量,且治疗毒副反应减轻。Object： To elaluate the quality of life of traditional Chinese medicine（ WD-5） and biological response modifiers with IL-2 IFN-α2b on renal cell cancer patients of stage Ⅲ、Ⅳ. Methods： 40 renal cell carcinoma cases of stageⅢ、Ⅳ were randomly assigned into 2 groups. According to random number table,enlisted patients were divided into observation group and control group.The combined treated group were given WD-5 and biological response modifiers with IL-2 IFN-α2b,and the control group were treated with biological response modifiers with IL-2 IFN-α2b scheme only. The efficacy was evaluated after 2 courses according to RECIST（ Response Evaluation Critera In Solid Tumors） criteria,and the clinical evaluating indexes such as clinical symptom amelioration,Karnofsky score,tumor marks,The T lymphocyte subsets and the quality of life（ QOL） and the toxicity and feasible with tolerable adverse reactions. Result：The trail group displayed more effective lightening the clinical symptoms,enhancing the quality of life and the physical strength（ KPS score）,improving immunologic function,reducing the level of tumor marker,raising patients＇ quality of life and reducing toxicity.

关 键 词：微调五号方 生物反应调节剂 肾癌 中医药 临床研究 

分 类 号：R737.11[医药卫生—肿瘤]